Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study).

Authors

Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, David Chee Eng Ng, Charlene Yu Lin Tang, Wei Ying Tham, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kae Jack Tay, Kenneth Chen, Sue Ping Thang

Published in

Asia-Pacific journal of clinical oncology. May 29, 2025. Epub May 29, 2025.

Abstract

Prostate cancer is the second most common cancer and the leading cause of cancer-related deaths in men. Patients with metastatic castration-resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks. This study evaluates the safety and efficacy of [¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT) in this high-risk group within an Asian population.
We conducted a retrospective analysis of 48 mCRPC patients with PSMA-avid diffuse bone metastases treated with [¹⁷⁷Lu]Lu-PSMA-RLT between May 9, 2018 and Jan 10, 2023. Patients received up to 4 to 6 initial therapy cycles, with additional cycles considered for those who responded initially but later progressed. Primary and secondary endpoints included overall survival (OS), PSA progression-free survival (PFS), PSA response, clinical response, and toxicity assessment.
Median OS was 9.3 months. Any PSA response was observed in 75% of patients. Notably, 48% achieved a ≥50% PSA reduction, correlating with a longer median OS (11.6 vs. 8.6 months, p = 0.03). Median PSA PFS was 3.2 months, with improved outcomes observed in patients achieving ≥50% PSA reduction (6.0 vs. 1.8 months, p < 0.0001). Pain relief was reported in 43% of patients, with a median pain score reduction of 5 points. The most common adverse effect was hepatotoxicity, with anemia in 27%, neutropenia in 27%, and thrombocytopenia in 21%.
[¹⁷⁷Lu]Lu-PSMA-RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [¹⁷⁷Lu]Lu-PSMA-RLT as a viable treatment option for this challenging population.

PMID:
40442869
Bibliographic data and abstract were imported from PubMed on 30 May 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.